




MERCK

Annual Meeting of Shareholders


May 25, 2021

Forward-looking statement

This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, uncertainties as to the timing of the proposed spinoff; uncertainties as to the status of any required regulatory approvals; the possibility that various conditions to the consummation of the spinoff may not be satisfied; the effects of disruption from the transactions contemplated in connection with the spinoff; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; the impact of the global outbreak of novel coronavirus disease (COVID-19); global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K, Organon’s Registration Statement on Form 10 (File No. 001-40235) and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).



MERCK

Annual Meeting of Shareholders

May 25, 2021

Board of directors



Leslie A. Brun




Mary Ellen Coe



Pamela J. Craig



Kenneth C. Frazier




Thomas H. Glocer




Risa J. Lavizzo-Mourey, M.D.




Paul B. Rothman, M.D.



Patricia F. Russo




Christine E. Seidman, M.D.



Inge G. Thulin



Kathy J. Warden



Peter C. Wendell



Stephen L. Mayo, Ph.D.

Retiring board member




Thomas R. Cech, Ph.D.

Executive committee




Kenneth C. Frazier




Robert M. Davis




Sanat Chattopadhyay



Frank Clyburn



Richard R. DeLuca Jr.



Julie L. Gerberding, M.D.,
M.P.H.



Dean Y. Li, M.D.,
Ph.D.




Caroline Litchfield




Steven C. Mizell



David Williams



Jennifer Zachary



MERCK

Merck's vision
and mission:
to save and
improve lives





COVID-19 response

COVID-19 therapeutic developments & collaborations



Full-year 2020 highlights



Merck

FY 2020
WORLDWIDE SALES

\$48.0B

2% growth
4% ex-exchange



Pharmaceutical sales

\$43.0B

3% growth
4% ex-exchange

Key drivers

STRONG GROWTH FROM
KEYTRUDA, LYNPARZA, LENVIMA,
PNEUMOVAX 23 AND BRIDION




Animal Health sales

\$4.7B

7% growth
10% ex-exchange


Key drivers

DRIVEN BY THE ACQUISITION OF
ANTELLIQ AND SALES OF
BRAVECTO




MERCK







MERCK



ORGANON





MERCK



Research and development highlights

Annual Meeting of Shareholders

May 25, 2021

Dean Y. Li



Notable approvals in 2020




KEYTRUDA (7), LYNPARZA (2), KOSELUGO, GARDASIL 9 and RECARBRIO



KEYTRUDA (2) and LENVIMA



LYNPARZA (3)



KEYTRUDA (2), LYNPARZA (3) and SILGARD9



ERVEBO approved in DRC, Burundi, Ghana and Zambia

Progressing molnupiravir as quickly as possible



Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19


Phase 3 MOVE-OUT Study of Molnupiravir in Outpatients to Proceed, Phase 2/3 MOVE-IN Study in Hospitalized Patients Will Not Proceed

Multiple anticipated approvals for 2021

New molecular entity	Regulatory status	Therapeutic area
VERQUVO	APPROVED (January)	Chronic heart failure in adults
15-Valent pneumo- conjugate vaccine	Target action: July	Pneumococcal disease (adults)
Belzutifan	Target action: September	Von Hippel-Lindau Disease-associated renal cell carcinoma
Gefapixant	Target action: December	Refractory or unexplained chronic cough in adults

Thank you





MERCK

Board of directors



Leslie A. Brun




Mary Ellen Coe



Pamela J. Craig



Kenneth C. Frazier




Thomas H. Glocer



Risa J. Lavizzo-Mourey, M.D.




Paul B. Rothman, M.D.



Patricia F. Russo




Christine E. Seidman, M.D.



Inge G. Thulin




Kathy J. Warden



Peter C. Wendell



Stephen L. Mayo, Ph.D.



MERCK